v3.26.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash provided (required) by operating activities of continuing operations:    
Net income (loss) $ (2,532.8) $ (516.4)
Discontinued operations, net of income taxes 50.2 4.0
Income (loss) from continuing operations (2,482.6) (512.4)
Adjustments from income from continuing operations to cash provided (required) by operating activities of continuing operations:    
Depreciation and amortization 124.0 130.5
Adjustments for commercial actions [1] 671.6 0.0
Restructuring and other charges (income) 779.9 349.0
Non-cash adjustments for India held for sale business 75.1 282.2
Deferred income taxes 786.3 106.1
Pension and other postretirement benefits 9.5 10.7
Share-based compensation 18.0 17.9
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:    
Trade receivables, net 193.4 (311.6)
Guarantees of vendor financing 5.8 (42.8)
Advance payments from customers (452.6) (453.8)
Accrued customer rebates 93.8 342.5
Inventories (194.3) (146.6)
Accounts payable, trade and other (60.7) (28.2)
Income taxes 110.2 (135.4)
Pension and other postretirement benefit contributions (5.4) (2.7)
Environmental spending, continuing, net of recoveries (26.7) (23.8)
Restructuring and other spending [2] (115.1) (81.0)
Change in other operating assets and liabilities, net [3] 238.5 (163.9)
Cash provided (required) by operating activities of continuing operations (231.3) (663.3)
Cash provided (required) by operating activities of discontinued operations:    
Environmental spending, discontinued, net of recoveries (25.1) (29.4)
Other discontinued spending (29.1) (24.3)
Cash provided (required) by operating activities of discontinued operations (54.2) (53.7)
Cash provided (required) by investing activities of continuing operations:    
Capital expenditures (29.7) (70.3)
Acquisitions, including cost and equity method, net (0.6) (2.1)
Proceeds from (disbursements for) the sale of the GSS business (0.2) (10.8)
Other investing activities 12.3 (1.2)
Cash provided (required) by investing activities of continuing operations (18.2) (84.4)
Cash provided (required) by financing activities of continuing operations:    
Increase (decrease) in short-term debt (583.6) 930.3
Financing fees and premiums [4] (19.1) (14.6)
Repayments of long-term debt (500.0) (500.1)
Proceeds from borrowing of long-term debt 1,200.0 750.0
Proceeds from issuance of common stock [5] 403.2 0.2
Fees associated with issuance of common stock [5] (8.0) 0.0
Acquisition of noncontrolling interest 0.0 (8.6)
Distributions to noncontrolling interests (3.0) (5.0)
Dividends paid [6] (30.4) (218.4)
Other repurchases of common stock (1.3) (1.7)
Cash provided (required) by financing activities of continuing operations 457.8 932.1
Effect of exchange rate changes on cash and cash equivalents (2.8) 9.7
Increase (decrease) in cash and cash equivalents 151.3 140.4
Cash and cash equivalents, beginning of period 584.5 357.3
Cash and cash equivalents, end of period $ 735.8 $ 497.7
[1] In response to challenging market conditions, we implemented comprehensive commercial actions to reflect pricing adjustments made on select products held by channel customers in key markets and modify the pricing and rebate model in North America.
[2] In addition to cash payments shown in our roll forward of restructuring reserves in Note 8 to our consolidated financial statements included within this Form 10-Q, the restructuring and other spending amount above for the nine months ended September 30, 2026 includes spending of $18.3 million primarily in connection with the India held for sale business. For additional detail on restructuring and other charges activities, see Note 8.
[3] Changes in all periods primarily represent timing of payments associated with all other operating assets and liabilities. The change during the nine months ended September 30, 2026 includes $200.0 million of cash received as an initial prepurchase payment in connection with the licensing agreement for rimisoxafen entered into in June 2026. For more details on the transaction, refer to Note 3.
[4] Includes the make-whole premium paid in connection with the early redemption of certain debt instruments during the nine months ended September 30, 2025.
[5] During the nine months ended September 30, 2026, Tessenderlo Group purchased approximately 30 million shares at a price of $13.30 per share representing a minority equity investment in FMC. See Note 13 for more information on the transaction.
[6] See Note 13 regarding the quarterly cash dividend.